Dacarbazine mediates antimelanoma effects via NK cells

Melanoma is a highly chemoresistant and metastatic tumor that, in the absence of BRAF mutations, is generally treated with the alkylating agent dacarbazine (DTIC). We discovered that DTIC upregulates the expression of NKG2D ligands on tumor cells, leading to the activation of natural killer (NK) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Hervieu, Alice, Mignot, Grégoire, Ghiringhelli, François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654594/
https://www.ncbi.nlm.nih.gov/pubmed/23734324
http://dx.doi.org/10.4161/onci.23714
_version_ 1782269588152516608
author Hervieu, Alice
Mignot, Grégoire
Ghiringhelli, François
author_facet Hervieu, Alice
Mignot, Grégoire
Ghiringhelli, François
author_sort Hervieu, Alice
collection PubMed
description Melanoma is a highly chemoresistant and metastatic tumor that, in the absence of BRAF mutations, is generally treated with the alkylating agent dacarbazine (DTIC). We discovered that DTIC upregulates the expression of NKG2D ligands on tumor cells, leading to the activation of natural killer (NK) and CD8(+) T cells. These observations underscore the immunogenic properties of DTIC and provide a rationale to combine DTIC with immunotherapeutic agents.
format Online
Article
Text
id pubmed-3654594
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-36545942013-06-03 Dacarbazine mediates antimelanoma effects via NK cells Hervieu, Alice Mignot, Grégoire Ghiringhelli, François Oncoimmunology Author's View Melanoma is a highly chemoresistant and metastatic tumor that, in the absence of BRAF mutations, is generally treated with the alkylating agent dacarbazine (DTIC). We discovered that DTIC upregulates the expression of NKG2D ligands on tumor cells, leading to the activation of natural killer (NK) and CD8(+) T cells. These observations underscore the immunogenic properties of DTIC and provide a rationale to combine DTIC with immunotherapeutic agents. Landes Bioscience 2013-04-01 2013-04-01 /pmc/articles/PMC3654594/ /pubmed/23734324 http://dx.doi.org/10.4161/onci.23714 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Hervieu, Alice
Mignot, Grégoire
Ghiringhelli, François
Dacarbazine mediates antimelanoma effects via NK cells
title Dacarbazine mediates antimelanoma effects via NK cells
title_full Dacarbazine mediates antimelanoma effects via NK cells
title_fullStr Dacarbazine mediates antimelanoma effects via NK cells
title_full_unstemmed Dacarbazine mediates antimelanoma effects via NK cells
title_short Dacarbazine mediates antimelanoma effects via NK cells
title_sort dacarbazine mediates antimelanoma effects via nk cells
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654594/
https://www.ncbi.nlm.nih.gov/pubmed/23734324
http://dx.doi.org/10.4161/onci.23714
work_keys_str_mv AT hervieualice dacarbazinemediatesantimelanomaeffectsviankcells
AT mignotgregoire dacarbazinemediatesantimelanomaeffectsviankcells
AT ghiringhellifrancois dacarbazinemediatesantimelanomaeffectsviankcells

Ejemplares similares